ClinicalTrials.gg
CompletedNCT05624216Updated Nov 22, 2022

Radiofrequency and Targeted Pressure Energy for Cellulite Reduction

An interventional study of BTL-084 in Cellulite, Cellulitis and Cellulitis of Leg, sponsored by BTL Industries Ltd.. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-22.

Sponsored by BTL Industries Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2020, 6 years 7 months ago, and no results have been posted to the registry.
  • Registered 3 years 3 months after the study started (first participant enrolled Jul 2019, registered Nov 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

This study will evaluate the clinical efficacy and safety of radiofrequency heating and targeted pressure energy for reduction in the appearance or cellulite. The study is a prospective multi-center open-label single-arm study. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits - 1, 3 and 6 months after the last therapy visit. All of the study subjects will receive the treatment with the subject device.

Read the detailed description

This study will evaluate the clinical efficacy and safety of radiofrequency heating and targeted pressure energy for reduction in the appearance or cellulite. The study is a prospective multi-center open-label single-arm study. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits - 1, 3 and 6 months after the last therapy visit. All of the study subjects will receive the treatment with the subject device.

At the baseline visit subject's weight will be recorded, together with hip and thigh circumference. In addition, photographs of the treated area will be taken.

The treatment administration phase will consist of four (4) treatments, delivered in 2-4 weeks. The applicator will be applied over the treatment area.

At the last therapy visit, the subject's weight will be recorded, together with hip and thigh circumference. Photographs of the treated area will be taken. In addition, subjects will receive Subject Satisfaction Questionnaire and Therapy Comfort Questionnaire to fill in.

Safety measures will include documentation of adverse events (AE). Following each treatment administration and at all of the follow-up visits, subjects will be checked for immediate post-procedure adverse event assessment.

02

Conditions studied

  • Cellulite
  • Cellulitis
  • Cellulitis of Leg
03

In context

Cellulite

71 studies on the registry are indexed under Cellulite; 3 are open to participants now.

This study's enrollment of 28 is below the median of 34 across 65 interventional studies indexed under Cellulite.

Browse Cellulite studies →

Lead sponsor

BTL Industries Ltd. is the lead sponsor of 77 studies on the registry; 5 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily signed form
  • Age ≥ 21 years
  • Subject suffer from Grade 2 or Grade 3 cellulite as per Nürnberger-Muller Scale
  • Subject did not experience weight change exceeding 2.5 kg (5 lb) in the preceding month
  • ≤ 33 kg/m2
  • Women of are required to use measures during the whole duration of the study
  • Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote skin tightening and cellulite reduction during study participation
  • Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation

Exclusion criteria

Exclusion Criteria:

  • Bacterial or viral infection, acute inflammations
  • Impaired immune system
  • disease
  • Diabetes
  • Herpes Simplex
  • Isotretinoin in the past 12 months
  • Scleroderma
  • Radiation therapy
  • Burns in the treatment area
  • Poor healing in the treatment area
  • Metal implants
  • Implantable pacemaker or automatic defibrillator / cardioverter
  • Ablative / non-ablative cosmetic intervention (deep peeling) in the past 3 months
  • Cancer and tumor diseases
  • Active collagen diseases
  • Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)
  • Pregnancy / nursing or IVF procedure
  • Acute neuralgia and neuropathy
  • Blood disorders, risk of bleeding, bleeding tissues, peptic ulcers
  • Eczema
  • Rosacea
  • Febrile conditions
  • Kidney or liver failure
  • Pronounced edemas, ascites, exudates
  • Sensitivity disorders in the treatment area
  • Varicose veins
  • Local therapy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    BTL-084 Treatment

    Radiofrequency and targeted pressure energy devices for the treatment of cellulite

    Device: BTL-084

Interventions

  • DeviceBTL-084

    Radiofrequency and targeted pressure energy devices for the treatment of cellulite

    Also known as: Emtone

06

What researchers measure

Primary outcomes

  1. Evaluation of cellulite severity change based on photographs before and after the study procedure according to the Cellulite Severity Scale

    Three independent evaluators will evaluate photographs for a level of cellulite severity by assigning a score according to the Cellulite Severity Scale (CSS) validated by Hexsel et al. After follow-up visits are conducted, evaluators will be given a set of the coded photographs from each subject for an evaluation. The Cellulite Severity Scale evaluates five key morphological features of cellulite; number of depressions, depth of depressions, clinical appearance of evident raised lesions, presence of flaccidity and the grade of cellulite. Each item is graded from 0 to 3, allowing final classification of cellulite as mild, moderate and severe.

    Time frame: 6 months

  2. Photography evaluation according to the Global Aesthetic Improvement scale

    Three independent evaluators will evaluate photographs for a level of appearance change by assigning a score according to the Global Aesthetic Improvement scale, where the lowest possible grade is (-1), worsened state and the highest is (3) very much improved.

    Time frame: 6 months

  3. Hip and Thigh Circumference Measure

    Hip and thigh circumference measurements will be conducted at the baseline visit, after the last treatment and during all follow-up visits.

    Time frame: 6 months

Secondary outcomes

  1. Therapy Comfort

    The 10-point scale will be used for evaluating the comfort during the study treatment. Subjects will be evaluating the comfort/discomfort on a scale from 1 ("No discomfort") to 10 ("Unbearable discomfort")

    Time frame: 6 months

  2. Subject Satisfaction

    The 5-point Likert scale Satisfaction questionnaire will be used to evaluate the participant's satisfaction with the therapy outcome. The subjects will be answering questions with possible answers varying from "Strongly disagree" to "Strongly agree"

    Time frame: 6 months

07

Study locations

1 site
  • Dr. Busso Cosmetic Dermatology
    Coconut Grove, Florida 33133, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Apr 2020, 8 months.

Of 20 interventional studies with no phase under Cellulite, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 22, 2022
StartActual
Jul 30, 2019
Primary completionActual
Apr 8, 2020
CompletionActual
Oct 25, 2021
Last update
Nov 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05624216
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
Jul 30, 2019
Primary completion
Apr 8, 2020
Completion
Oct 25, 2021
Last update
Nov 22, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion